background
infl
uenza
import
caus
morbid
mortal
worldwid
treatment
option
scarc
new
drug
novel
mechan
action
need
aim
assess
effi
caci
safeti
nitazoxanid
thiazolid
antiinfect
treatment
acut
uncompl
infl
uenza
doubleblind
randomis
placebocontrol
phase
trial
primari
care
clinic
usa
dec
april
enrol
particip
age
year
fever
least
one
respiratori
symptom
one
constitut
symptom
infl
uenza
within
h
symptom
onset
randomli
assign
particip
receiv
either
nitazoxanid
mg
nitazoxanid
mg
placebo
twice
daili
day
ratio
follow
day
randomis
list
comput
gener
done
block
three
sponsor
investig
studi
monitor
patient
laboratori
personnel
mask
treatment
alloc
studi
primari
endpoint
time
fi
rst
dose
allevi
symptom
primari
analysi
intentiontotreat
particip
infl
uenza
infect
confi
rmed
rtpcr
cultur
baselin
trial
regist
clinicaltrialsgov
number
particip
screen
enrol
randomli
assign
receiv
placebo
twice
day
receiv
nitazoxanid
mg
twice
day
receiv
nitazoxanid
mg
day
median
durat
symptom
particip
receiv
placebo
h
ci
compar
h
receiv
mg
nitazoxanid
h
receiv
mg
nitazoxanid
advers
event
similar
three
group
common
headach
report
patient
enrol
placebo
group
patient
lowdos
group
patient
highdos
group
diarrhoea
report
seven
patient
placebo
group
four
patient
enrol
lowdos
group
patient
highdos
group
interpret
treatment
nitazoxanid
mg
twice
daili
day
associ
reduct
durat
symptom
particip
acut
uncompl
infl
uenza
studi
warrant
confi
rm
fi
nding
assess
effi
caci
drug
alon
combin
exist
drug
serious
ill
patient
risk
infl
uenza
complic
fund
romark
laboratori
lc
infl
uenza
contagi
respiratori
ill
caus
infl
uenza
b
c
virus
infect
global
concern
result
million
case
sever
diseas
death
annual
usa
season
infl
uenza
aff
ectson
popul
per
year
lead
roughli
hospit
admiss
death
threat
pandem
infl
uenza
caus
emerg
virus
avian
recent
major
concern
potenti
eff
ect
human
life
economi
nation
secur
function
societi
widespread
adamantin
resist
treatment
infl
uenza
present
limit
neuraminidas
inhibitor
oseltamivir
zanamivir
new
drug
novel
mechan
action
use
alon
combin
neuraminidas
inhibitor
urgent
need
improv
treatment
outcom
mitig
risk
resist
nitazoxanid
fi
rstinclass
thiazolid
antiinfect
inhibit
replic
broad
rang
infl
uenza
virus
includ
neuraminidas
inhibitorresist
strain
block
matur
viral
haemagglutin
posttransl
level
cell
cultur
studi
nitazoxanid
act
synergist
neuraminidas
inhibitor
repeat
passag
infl
uenza
virus
subinhibitori
concentr
drug
proven
unsuccess
select
resist
strain
suggest
high
barrier
resist
nitazoxanid
also
inhibit
replic
respiratori
virus
includ
parainfl
uenza
viru
coronaviru
respiratori
syncyti
viru
cell
cultur
nitazoxanid
alinia
romark
laboratori
lc
licens
usa
treatment
diarrhoea
caus
cryptosporidium
parvum
giardia
lamblia
wide
use
throughout
latin
america
treatment
intestin
parasit
infect
mg
controlledreleas
tablet
develop
deliv
plasma
con
centrat
suitabl
treatment
viral
respiratori
infect
aim
assess
safeti
effi
caci
two
diff
erent
dose
nitazoxanid
reduc
durat
symptom
acut
un
complic
infl
uenza
design
phase
randomis
clinic
trial
consult
us
food
drug
administr
fda
guidanc
industri
publish
clinic
trial
oseltamivir
zanamivir
effi
caci
nitazoxanid
treatment
acut
uncompl
infl
uenza
establish
studi
serious
ill
patient
patient
high
risk
complic
infl
uenza
variabl
diseas
diffi
culti
defi
ning
margin
noninferior
exist
drug
use
placebo
clearli
assess
activ
drug
mg
mg
dose
nitazoxanid
use
studi
select
basi
past
experi
pharmacokinet
toler
recruit
patient
primari
care
clinic
usa
main
elig
criteria
particip
age
year
oral
temperatur
greater
least
one
respiratori
symptom
cough
sore
throat
nasal
discharg
nasal
congest
sneez
one
constitut
symptom
headach
myalgia
sweat
chill
fatigu
symptom
durat
h
less
confi
rmation
infl
uenza
laboratori
local
commun
mile
radiu
site
exclud
sever
ill
requir
admiss
hospit
high
risk
infl
uenzarel
complic
accord
infecti
diseas
societi
america
guidelin
present
us
center
diseas
control
prevent
cdc
criteria
vaccin
season
infl
uenza
aug
treatment
dose
oseltamivir
zanamivir
amantadin
rimantadin
nitazoxanid
investi
gation
drug
therapi
within
day
screen
activ
respiratori
allergi
preexist
ill
could
place
particip
unreason
increas
risk
central
institut
review
board
irb
local
irb
centr
approv
protocol
trial
done
investig
new
drug
applic
fda
done
accord
guidelin
set
world
medic
assembl
declar
helsinki
last
amend
seoul
everi
particip
guardian
gave
written
inform
consent
particip
younger
year
age
provid
written
assent
randomis
list
comput
gener
everi
particip
randomli
assign
ratio
receiv
either
two
bottl
contain
nitazoxanid
mg
tablet
nitazoxanid
mg
group
one
bottl
contain
nitazoxanid
mg
tablet
plu
one
bottl
contain
placebo
tablet
nitazoxanid
mg
group
two
bottl
placebo
placebo
group
nitazoxanid
tablet
placebo
tablet
packag
white
highdens
polyethylen
bottl
contain
ten
tablet
particip
instruct
take
two
tablet
one
bottl
twice
daili
food
day
randomis
list
medic
packag
prepar
independ
third
parti
maintain
blind
trial
databas
lock
randomis
done
block
three
mask
studi
medic
three
treatment
kit
per
block
assign
everi
investig
sequenti
assign
treatment
number
particip
enrol
randomis
list
mask
studi
particip
sponsor
investig
studi
monitor
patient
laboratori
personnel
immedi
obtain
inform
consent
verifi
elig
everi
patient
baselin
day
physic
examin
medic
histori
record
obtain
two
nasopharyng
swab
nylon
fl
ock
dri
swab
copan
diagnost
murrieta
ca
usa
blood
urin
sampl
laboratori
safeti
test
calcul
infl
uenza
antibodi
titr
studi
drug
dispens
particip
instruct
use
diari
twice
daili
roughli
everi
h
record
time
amount
everi
dose
studi
drug
symptom
sever
concomit
medic
advers
event
everi
diari
entri
particip
grade
nine
symptom
runni
nose
nasal
congest
sore
throat
cough
headach
muscl
ach
tired
fatigu
feverish
sweat
chill
scale
absent
mild
moder
sever
particip
complet
diari
least
studi
day
symptom
either
absent
mild
remain
least
h
studi
nurs
visit
telephon
everi
particip
daili
studi
day
review
symptom
check
infl
uenzarel
complic
particip
return
clinic
physic
examin
diari
review
day
day
obtain
blood
urin
sampl
laboratori
safeti
test
nasopharyng
swab
virolog
test
day
obtain
blood
sampl
measur
infl
uenza
antibodi
titr
day
ten
site
nurs
visit
particip
day
collect
two
nasopharyng
swab
select
particip
h
assess
pharmacokinet
immedi
fi
rst
dose
morn
day
h
last
dose
day
antivir
drug
infl
uenza
overthecount
cough
cold
medic
antiallergi
drug
respiratori
allergi
prohibit
studi
paracetamol
allow
necessari
fever
oral
temperatur
monitor
complianc
particip
return
bottl
medic
dispens
along
unus
medic
pill
count
record
laboratori
safeti
test
haematolog
test
complet
blood
count
diff
erenti
blood
chemistri
test
comprehens
metabol
panel
lipid
profi
le
urinalysi
baselin
day
north
shorelij
health
system
laboratori
collabor
barc
usa
lake
success
ny
usa
virolog
test
nasopharyng
swab
place
ml
viral
transport
medium
transport
refriger
central
laboratori
within
h
swab
sampl
elut
divid
aliquot
immedi
frozen
naso
pharyng
swab
baselin
day
cultur
infl
uenza
virus
analys
rtpcr
prodesseprofl
u
genprob
prodess
waukesha
wi
usa
infl
uenza
b
luminex
xtag
rvp
assay
luminex
corpor
austin
tx
usa
detect
infl
uenza
nonspecifi
c
subtyp
infl
uenza
subtyp
season
infl
uenza
b
respiratori
syncyti
viru
respiratori
syncyti
viru
b
adenoviru
human
metapneumoviru
enteroviru
rhinoviru
parainfl
uenza
virus
coronavirus
sampl
posit
infl
uenza
also
analys
realtim
rtpcr
infl
uenza
basi
cdc
protocol
particip
posit
infl
uenza
b
cultur
rtpcr
baselin
viral
titr
measur
baselin
subsequ
collect
point
calcul
titr
log
tissu
cultur
infect
dose
tcid
ml
log
rna
copi
quantit
rtpcr
method
develop
valid
north
shorelij
health
system
laboratori
particip
diagnos
infl
uenza
cultur
rtpcr
baselin
measur
infl
uenza
antibodi
titr
haemagglutin
inhibit
assay
serum
sampl
obtain
baselin
day
assess
eff
ect
treatment
humor
immun
respons
refer
antigen
use
measur
antibodi
titr
b
assess
potenti
resist
test
virus
cultur
nasopharyng
swab
sampl
nitazoxanidetr
particip
day
day
correspond
viru
sampl
baselin
day
suscept
tizoxanid
previous
describ
primari
endpoint
clinic
trial
time
fi
rst
dose
allevi
symptom
base
patientreport
symptom
data
method
valid
clinic
trial
oseltamivir
zanamivir
deem
symptom
particip
allevi
begin
fi
rst
h
period
throughout
symptom
grade
either
absent
mild
addit
seven
symptom
cough
nasal
obstruct
sore
throat
fatigu
headach
myalgia
feverish
monitor
oseltamivir
zanamivir
studi
particip
enrol
studi
also
monitor
runni
nose
sweat
chill
secondari
endpoint
chang
infl
uenza
viru
titr
time
time
cessat
viral
shed
time
allevi
individu
symptom
symptom
sever
complic
infl
uenza
time
return
normal
activ
time
lost
work
infl
uenza
antibodi
respons
analys
data
accord
statist
analysi
plan
develop
start
clinic
trial
plan
call
two
primari
effi
caci
analys
compar
time
fi
rst
dose
allevi
symptom
nitazoxanid
mg
versu
placebo
nitazoxanid
mg
versu
placebo
use
kaplanmei
surviv
analysi
cox
proport
hazard
test
includ
geograph
locat
factor
twosid
check
proport
hazard
assumpt
includ
interact
term
covari
log
time
visual
inspect
graph
log
log
surviv
versu
log
time
hazard
proport
use
prenticewilcoxon
test
analys
popul
consist
particip
receiv
least
one
dose
studi
drug
laboratoryconfi
rmed
infl
uenza
infect
rtpcr
cultur
baselin
sensit
analys
assess
eff
ect
paracetamol
use
repeat
primari
analysi
includ
paracetamol
use
interact
treatment
group
censor
data
assum
particip
censor
data
day
allevi
symptom
sampl
size
calcul
assum
median
time
symptom
allevi
placebo
group
day
diff
erenc
median
time
symptom
allevi
placebo
nitazoxanid
treatment
group
day
dropout
rate
logrank
test
due
two
primari
effi
caci
analys
power
sampl
size
randomli
assign
treat
particip
laboratoryconfi
rmed
infl
uenza
per
group
calcul
also
secondari
effi
caci
analys
time
allevi
symptom
particip
receiv
studi
drug
irrespect
laboratori
evid
infect
particip
without
confi
rmed
respiratori
viru
infect
statist
comparison
chang
viral
titr
mix
model
repeat
measur
includ
baselin
viral
titr
treatment
group
geograph
locat
safeti
popul
includ
particip
receiv
least
one
dose
studi
medic
analys
done
sa
softwar
version
sa
institut
cari
nc
usa
trial
regist
clinicaltrialsgov
number
sponsor
design
protocol
engag
contract
research
organis
select
initi
monitor
close
studi
site
collect
analys
data
sponsor
wrote
studi
report
author
particip
interpret
data
write
manuscript
decis
submit
manuscript
public
author
full
access
data
dec
april
enrol
particip
infl
uenzalik
ill
peopl
screen
centr
usa
fi
gure
studi
termin
plan
number
patient
infect
infl
uenza
end
infl
uenza
season
randomis
patient
charact
istic
well
balanc
group
tabl
particip
enrol
diagnos
respiratori
viru
infect
baselin
includ
infl
uenza
b
tabl
demograph
diseaserel
characterist
particip
similar
three
treatment
group
tabl
treatment
nitazoxanid
mg
twice
daili
day
signifi
cantli
decreas
time
fi
rst
dose
allevi
symptom
compar
placebo
particip
confi
rmed
infl
uenza
fi
gure
tabl
time
symptom
allevi
also
decreas
patient
given
nitazoxanid
mg
compar
given
placebo
diff
erenc
signifi
cant
use
prenticewilcoxon
test
analys
proport
hazard
assumpt
requir
use
cox
model
violat
interact
mg
nitazoxanid
treatment
group
log
time
signifi
cant
time
symptom
allevi
particip
still
receiv
symptom
relief
medic
paracetamol
sensit
analys
popul
confi
rmed
infl
uenza
assess
eff
ect
censor
data
use
paracetamol
primari
endpoint
particip
censor
data
dropout
without
symptom
allevi
last
diari
assess
assum
time
allevi
symptom
day
analysi
result
similar
primari
effi
caci
analysi
favour
nitazoxanid
mg
compar
placebo
data
shown
particip
enrol
popul
confi
rmed
infl
uenza
report
take
paracetamol
studi
allow
studi
protocol
proport
particip
take
paracetamol
similar
three
treatment
group
particip
placebo
group
nitazoxanid
mg
group
nitazoxanid
mg
group
repeat
primari
analysi
includ
paracetamol
use
interact
treatment
group
particip
receiv
nitazoxanid
mg
shorter
time
symptom
allevi
receiv
placebo
studi
enrol
particip
within
h
symptom
onset
wherea
studi
neuraminidas
inhibitor
particip
enrol
within
h
assess
eff
ect
variabl
analys
particip
enrol
within
h
symptom
onset
posthoc
analys
diff
erenc
nitazoxanid
mg
vs
placebo
respons
subgroup
infect
infl
uenza
b
similar
tabl
analys
particip
treat
particip
viru
identifi
ed
baselin
time
fi
rst
dose
allevi
symptom
signifi
cantli
lower
mg
group
placebo
group
tabl
investig
particip
infect
individu
viral
infect
make
meaning
analys
anoth
diff
erenc
design
studi
earlier
studi
neuraminidas
inhibitor
score
nine
symptom
instead
seven
use
two
addit
symptom
runni
nose
sweat
chill
aff
ect
time
allevi
symptom
six
particip
three
given
placebo
one
given
nitazoxanid
mg
two
given
nitazoxanid
mg
analysi
base
seven
symptom
use
oseltamivir
studi
show
median
time
allevi
symptom
h
ci
placebo
group
h
nitazoxanid
mg
treatment
group
h
nitazoxanid
mg
treatment
group
baselin
cough
nasal
congest
persist
symptom
particip
infect
infl
uenza
median
time
allevi
placebo
group
cough
h
ci
nasal
congest
h
treatment
nitazoxanid
mg
associ
decreas
median
durat
symptom
h
ci
cough
h
nasal
congest
nine
symptom
particip
infect
infl
uenza
mean
symptom
scorehour
symptom
sever
score
multipli
hour
sum
everi
particip
baselin
allevi
symptom
sd
placebo
group
nitazoxanid
mg
treatment
group
nitazoxanid
mg
treatment
group
wherea
treat
particip
scorehour
placebo
group
mg
treatment
group
mg
treatment
group
complic
infl
uenza
bronchiti
sinus
otiti
pneumonia
pleurisi
fairli
uncommon
popul
frequenc
signifi
cantli
diff
erent
treatment
group
event
placebo
compar
nitazoxanid
mg
treatment
group
nitazoxanid
mg
treatment
group
obtain
daili
nasopharyng
swab
baselin
day
particip
placebo
group
nitazoxanid
mg
treatment
group
nitazoxanid
mg
treatment
group
tcid
viral
titr
signifi
cantli
decreas
treatment
nitazoxanid
mg
group
compar
placebo
group
fi
gure
roughli
log
appar
within
h
initi
treatment
nitazoxanid
mg
group
continu
day
viral
shed
stop
almost
particip
placebo
group
reduct
tcid
viral
titr
also
record
nitazoxanid
mg
treatment
group
compar
placebo
group
although
diff
erenc
larg
nitazoxanid
mg
treatment
group
signifi
cant
fi
gure
reduct
viral
titr
detect
tcid
similar
dectect
rtpcr
except
magnitud
reduct
somewhat
smaller
measur
rtpcr
also
detect
noninfecti
viru
particl
median
time
cessat
viral
shed
h
ci
placebo
group
h
nitazoxanid
mg
treatment
group
h
nitazoxanid
mg
treatment
group
day
one
particip
placebo
group
posit
infl
uenza
infect
viral
cultur
infl
uenza
viru
detect
rtpcr
sampl
day
patient
placebo
group
patient
nitazoxanid
mg
treatment
group
patient
mg
treatment
group
cultur
infl
uenza
virus
nasopharyng
swab
taken
day
particip
treat
nitazoxanid
virus
present
sampl
inhibit
tizoxanid
eff
ectiv
concentr
similar
inhibit
virus
present
correspond
baselin
sampl
data
shown
assess
potenti
eff
ect
treatment
humor
immun
respons
measur
antibodi
titr
baselin
day
particip
laboratoryconfi
rmed
infl
uenza
rtpcr
viral
cultur
baselin
note
signifi
cant
diff
erenc
antibodi
titr
chang
baselin
day
proport
particip
laboratoryconfi
rmed
infl
uenza
seroprotect
antibodi
titr
seroconvert
fourfold
increas
antibodi
titr
day
treatment
group
seroconvers
rate
particip
placebo
group
nitazoxanid
mg
treatment
group
nitazoxanid
mg
treatment
group
analys
plasma
concentr
tizoxanid
fi
rst
h
dose
morn
day
six
particip
treat
nitazoxanid
mg
ten
particip
treat
nitazoxanid
mg
mean
maximum
plasma
concentr
tizoxanid
sd
nitazoxanid
mg
group
nitazoxanid
mg
mean
trough
concentr
nitazoxanid
mg
treatment
group
nitazoxanid
mg
group
mean
area
curv
auc
h
tizoxanid
plasma
concentr
hml
sd
nitazoxanid
mg
group
hml
nitazoxanid
mg
group
analysi
chang
tcid
viral
titr
particip
confi
rmed
infl
uenza
took
daili
nasopharyng
swab
statist
comparison
mix
model
repeat
measur
includ
baselin
viral
titr
treatment
group
geograph
locat
diff
erenc
nitazoxanid
mg
placebo
diff
erenc
nitazoxanid
mg
placebo
group
compar
none
placebo
group
event
probabl
attribut
colour
nitazoxanid
metabolit
mild
natur
rel
infrequ
chromaturia
particip
enrol
blind
studi
aff
ect
treatment
nitazoxanid
given
oral
mg
twice
daili
day
begin
less
h
symptom
onset
signifi
cantli
reduc
time
fi
rst
dose
allevi
symptom
particip
age
year
acut
uncompl
infl
uenza
mg
dose
produc
intermedi
respons
signifi
cantli
diff
er
placebo
group
trial
design
accord
regulatori
guidanc
consist
previou
trial
neuraminidas
inhibitor
oseltamivir
zanamivir
panel
reduct
time
allevi
symptom
median
diff
erenc
h
mg
group
rang
record
trial
neuraminadas
inhibitor
diff
erenc
size
treatment
eff
ect
one
trial
anoth
could
aris
result
diff
erenc
studi
design
eg
durat
symptom
time
enrol
popul
select
analysi
use
paracetamol
characterist
circul
infl
uenza
strain
eg
pathogen
drug
suscept
studi
enrol
particip
within
h
symptom
onset
wherea
clinic
trial
neuraminidas
inhibitor
enrol
particip
within
h
symptom
onset
time
symptom
allevi
fastest
subset
enrol
within
h
symptom
onset
nitazoxanid
mg
group
contrast
studi
neuraminidas
inhibitor
result
studi
show
potenti
treatment
benefi
particip
without
infl
uenza
document
viral
infect
h
reduct
time
allevi
symptom
mg
vs
placebo
comparison
treatment
eff
ect
nitazoxanid
neuraminidas
inhibitor
particip
confi
rmed
infl
uenza
infect
without
document
viral
infect
interest
goal
futur
trial
advers
event
profi
le
nitazoxanid
well
known
commerci
avail
sinc
global
market
treatment
intestin
infect
studi
use
new
controlledreleas
formul
nitazoxanid
design
specifi
calli
deliv
drug
blood
respiratori
tract
maintain
blood
concentr
h
mg
dose
group
drug
given
dose
higher
durat
therapi
longer
drug
approv
dose
treatment
intestin
infect
increas
dose
durat
result
signifi
cant
chang
known
sideeff
ect
profi
le
frequenc
sever
advers
event
signifi
cantli
diff
er
particip
group
studi
fi
nding
clinic
trial
need
confi
rmed
studi
limit
studi
includ
number
particip
fact
enrol
singl
infl
uenza
season
absenc
statist
signifi
canc
mg
treatment
group
might
refl
ect
absenc
statist
power
plan
number
particip
recruit
although
trial
enrol
particip
infl
uenza
b
examin
effi
caci
safeti
drug
infl
uenza
strain
anoth
season
would
benefi
cial
drug
seem
associ
resist
might
expect
mechan
action
studi
assess
potenti
resist
would
valuabl
furthermor
although
clinic
trial
shown
treatment
eff
ect
otherwis
healthi
particip
age
year
eff
ect
drug
still
need
studi
children
patient
seriou
ill
risk
infl
uenza
complic
